Breast Cancer Treatment Can Be Tough on the Heart
Publication date: Available online 14 November 2018Source: The American Journal of SurgeryAuthor(s): Erica Burkheimer, Leah Starks, Mariam Khan, Leon Oostendorp, Marianne K. Melnik, Mathew H. Chung, G. Paul WrightAbstractIntroductionObesity has been associated with negative oncologic outcomes in breast cancer.MethodsRetrospective review of patients with operable breast cancer at a single institution from 2009–2012. Patients with carcinoma in situ or metastatic disease were excluded. Variables included utilization of MRI, surgical treatment, perioperative, and long-term oncologic outcomes. Primary outcome was rate of ...
ConclusionIn summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.
Publication date: Available online 6 November 2018Source: Journal of Bone OncologyAuthor(s): Stella D'Oronzo, Robert Coleman, Janet Brown, Francesco SilvestrisAbstractBone metastases (BM) are a common complication of cancer, whose management often requires a multidisciplinary approach. Despite the recent therapeutic advances, patients with BM may still experience skeletal-related events and symptomatic skeletal events, with detrimental impact on quality of life and survival.A deeper knowledge of the mechanisms underlying the onset of lytic and sclerotic BM has been acquired in the last decades, leading to the development o...
In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.
Reconstruction with autologous fat transfer seems not to increase rate of locoregional recurrence
Condition: Breast Cancer Interventions: Drug: Nivolumab 360 mg+ paclitaxel 80 mg/m2; Drug: Doxorubicin 60 mg/m2+Cyclophosphamide 600 mg/m2; Drug: Nivolumab 360 mg+ Docetaxel* 75 mg/m2 +Trastuzumab 8 mg/kg +Pertuzumab 840 mg; Drug: Doxorubicin 60 mg/m2 +Cyclophosphamide 600 mg/m2 Sponsor: New York University School of Medicine Not yet recruiting
Condition: Triple Negative Breast Cancer (TNBC) Interventions: Biological: spartalizumab; Biological: LAG525; Drug: NIR178; Drug: capmatinib; Biological: MCS110; Biological: canakinumab Sponsor: Novartis Pharmaceuticals Not yet recruiting
Conditions: Breast Cancer Metastatic; Breast Cancer Interventions: Drug: Olaparib; Drug: Vorinostat Sponsors: Jenny C. Chang, MD; AstraZeneca Not yet recruiting
Condition: Triple Negative Breast Neoplasms Interventions: Drug: Durvalumab; Drug: Selumetinib; Drug: Capivasertib; Drug: Danvatirsen; Drug: Oleclumab; Drug: Paclitaxel Sponsor: AstraZeneca Not yet recruiting
Beloved Hollywood celebrities, famous politicians or members of the British royal family: no better advertisement for fitness tracker producers and health tech companies. As models, actors and actresses are highly influential people, their early adoption of digital solutions could also push the masses towards living more healthily with technologies. On the other hand, celebrities are inclined to follow questionable health trends, too, which go against decades of medical evidence. Those examples, everyone should rather reject. Wearables conquered Hollywood, the White House, and the British royal family Celebrities are all a...